Expression of mRNA for membrane-type 1, 2, and 3 matrix metalloproteinases in human laryngeal cancer

Chinese Medical Sciences Journal

Volumn 19, Issue 3, 2004, Pages 170-173

  Sun, Ya Nan ^a   Li, Yuan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Laryngeal cancer; Membrane type matrix metalloproteinases; Polymerase chain reaction

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MEMBRANE TYPE 2 MATRIX METALLOPROTEINASE; MEMBRANE TYPE 3 MATRIX METALLOPROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER INVASION; CLINICAL ARTICLE; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; LARYNX CANCER; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; PROTEIN EXPRESSION;

ADULT; AGED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LARYNGEAL NEOPLASMS; LARYNX; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; MIDDLE AGED; NEOPLASM INVASIVENESS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 5444250890     PISSN: 10019294     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their role in tumor invasion and metastasis. Eur J Cancer 2000;36:1621-30.
2. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99:157-66.
3. Yana I, Seiki M. MT-MMPs play pivotal roles in cancer dissemination. Clin Exp Metastasis 2002;19:209-15.
4. Lang R, Braun M, Sounni NE, et al. Crystal structure of the catalytic domain of MMP-16/MT3-MMP: characterization of MT-MMP specific features. J Mol Biol 2004;336:213-25.
5. Jiang A, Pei D. Distinct roles of catalytic and pexin-like domains in membrane-type matrix metalloproteinase (MMP)-mediated pro-MMP-2 activation and collagenolysis. J Biol Chem 2003;278:38765-71.
6. Ueno H, Nakamura H, Inoue M, et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 1997;57:2055-60.
7. Nakamura H, Ueno H, Yamashita K, et al. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res 1999;59:467-73.
8. Kang T, Yi J, Yang WR, et al. Functional characterization of MT3-MMP in transfected MDCK cells: progelatinase A activation and tubulogenesis in 3-D collagen lattice. FASEB J 2000;14:2559-68.
9. Kitagawa Y, Kunimi K, Uchibayashi T, et al. Expression of messenger RNAs for membrane-type 1, 2, and 3 matrix metalloproteinases in human renal cell carcinomas. J Urol 1999;162:905-9.
10. Nuttall RK, Pennington CJ, Taplin J, et al. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res 2003;1:333-45.
11. Sounni NE, Devy L, Hajitou A, et al. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 2002;16:555-64.
12. Kajita M, Itoha Y, Chibaa T, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001;153:893-904.